Nuvectis Pharma, Inc.
NVCT
$9.29
-$0.205-2.16%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 26.82% | -9.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 47.95% | -6.12% | |||
| Operating Income | -47.95% | 6.12% | |||
| Income Before Tax | -50.45% | 6.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -50.45% | 6.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -50.45% | 6.21% | |||
| EBIT | -47.95% | 6.12% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -45.98% | 8.02% | |||
| Normalized Basic EPS | -46.02% | 8.06% | |||
| EPS Diluted | -45.98% | 8.02% | |||
| Normalized Diluted EPS | -46.02% | 8.06% | |||
| Average Basic Shares Outstanding | 3.06% | 1.95% | |||
| Average Diluted Shares Outstanding | 3.06% | 1.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
